MedPath

Relationship Between Serum β2-Microglobulin and Infiltration of CD8+ in the Tumor Tissue of Hodgkin's Lymphoma Patients

Completed
Conditions
Hodgkin Lymphoma
Registration Number
NCT06564259
Lead Sponsor
Tishreen University
Brief Summary

In newly diagnosed Hodgkin lymphoma patients, pre-treatment Beta-2 Microglobulin (B2M) levels will be measured. A thorough baseline assessment will be performed using CT imaging, and tumor tissue samples will be collected for Immunohistochemical (IHC) analysis to quantify CD8+ cell infiltration. Patients will be closely monitored throughout their treatment, with a follow-up CT scan at the end of therapy to evaluate therapeutic response. This study aims to investigate the correlation between pre-treatment B2M levels and CD8+ immune cell infiltration in tumor tissues, assessing their potential as predictive markers for chemotherapy response.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
144
Inclusion Criteria
  • Newly diagnosed patients with Hodgkin lymphoma
  • No prior history of malignancy
  • Absence of primary or secondary immunodeficiencies
Exclusion Criteria
  • Patients who have previously undergone treatment
  • Patients with acute or chronic infections
  • Patients with renal disorders
  • Individuals with autoimmune diseases
  • HIV-positive patients

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Therapeutic response2-4 months

Achieving complete remission after chemotherapy

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Tishreen University

🇸🇾

Latakia, Syrian Arab Republic

Tishreen University
🇸🇾Latakia, Syrian Arab Republic
© Copyright 2025. All Rights Reserved by MedPath